Emmaus Life Sciences, Inc.
EMMA
$0.07
$0.019.23%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 124.28% | -17.62% | 17.01% | -38.34% | -47.61% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 124.28% | -17.62% | 17.01% | -38.34% | -47.61% |
| Cost of Revenue | 129.33% | -25.33% | -23.95% | -37.31% | -37.76% |
| Gross Profit | 124.00% | -16.83% | 21.25% | -38.41% | -48.07% |
| SG&A Expenses | -30.66% | -13.00% | -6.45% | -53.79% | -31.68% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -20.71% | -17.16% | -10.38% | -52.77% | -33.53% |
| Operating Income | 1,124.59% | 16.02% | 172.26% | 43.54% | -163.57% |
| Income Before Tax | 177.57% | -43.21% | -11.08% | -181.98% | 19.88% |
| Income Tax Expenses | 99.83% | 0.00% | 166.67% | 58,000.00% | -2,003.23% |
| Earnings from Continuing Operations | 217.97% | -43.13% | -11.61% | -213.63% | 48.03% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 217.97% | -43.13% | -11.61% | -213.63% | 48.03% |
| EBIT | 1,124.59% | 16.02% | 172.26% | 43.54% | -163.57% |
| EBITDA | 1,139.62% | 17.13% | 175.63% | 44.49% | -162.24% |
| EPS Basic | 207.30% | -30.14% | -10.22% | -213.64% | 48.41% |
| Normalized Basic EPS | 223.33% | -36.79% | -47.65% | -139.11% | -13.21% |
| EPS Diluted | 175.50% | -30.14% | -10.22% | -213.64% | 42.03% |
| Normalized Diluted EPS | 171.67% | -36.79% | -47.65% | -139.11% | -13.21% |
| Average Basic Shares Outstanding | 9.90% | 9.90% | 1.09% | 0.00% | 0.81% |
| Average Diluted Shares Outstanding | 88.74% | 9.90% | 1.09% | 0.00% | 0.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |